| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| March 17, 2023 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 95,950 | |
| June 8, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 | |
| June 4, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 151,357 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 183,689 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 180,118 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 179,737 | |
| March 19, 2021 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 151,357 | |
| February 2, 2016 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 152,500 | |
| June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 | |
| June 20, 2014 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 109,162 | |
| February 11, 2014 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 125,500 | |
| February 11, 2014 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 106,664 | |
| May 6, 2013 | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 86,667 | ||
| February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.49 | 145,000 | |
| February 25, 2011 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.49 | 70,000 | |
| February 19, 2010 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | $2.94 | 185,000 | |
| September 6, 2016 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,663 | -- | 316,213 | |
| December 22, 2003 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 41,287 | -- | -- | |
| May 23, 2005 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 44,300 | $0.40 | 664,395 | |
| February 11, 2014 | Director, CEO | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 44,444 | -- | 303,329 | |
| February 15, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 45,000 | $0.21 | 145,081 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 45,000 | -- | 248,245 | |
| July 25, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 46,838 | $4.27 | 243,942 | |
| February 25, 2020 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 47,000 | $1.16 | 54,298 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
